Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients

Justin M. Watts, Xin Victoria Wang, Mark R Litzow, Selina M. Luger, Hillard M. Lazarus, Peter A. Cassileth, Hugo F. Fernandez, Dan Douer, Lynette Zickl, Elisabeth Paietta, Jacob M. Rowe, Martin S. Tallman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.

Original languageEnglish (US)
Pages (from-to)901-906
Number of pages6
JournalLeukemia Research
Volume38
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Acute Myeloid Leukemia
Young Adult
Recurrence
Karyotype
Chromosome Aberrations
Survival

Keywords

  • Acute myeloid leukemia
  • Clinical trials
  • Late relapse
  • Normal cytogenetics
  • Outcomes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure : The ECOG experience in over 1200 patients. / Watts, Justin M.; Wang, Xin Victoria; Litzow, Mark R; Luger, Selina M.; Lazarus, Hillard M.; Cassileth, Peter A.; Fernandez, Hugo F.; Douer, Dan; Zickl, Lynette; Paietta, Elisabeth; Rowe, Jacob M.; Tallman, Martin S.

In: Leukemia Research, Vol. 38, No. 8, 2014, p. 901-906.

Research output: Contribution to journalArticle

Watts, JM, Wang, XV, Litzow, MR, Luger, SM, Lazarus, HM, Cassileth, PA, Fernandez, HF, Douer, D, Zickl, L, Paietta, E, Rowe, JM & Tallman, MS 2014, 'Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients', Leukemia Research, vol. 38, no. 8, pp. 901-906. https://doi.org/10.1016/j.leukres.2014.05.018
Watts, Justin M. ; Wang, Xin Victoria ; Litzow, Mark R ; Luger, Selina M. ; Lazarus, Hillard M. ; Cassileth, Peter A. ; Fernandez, Hugo F. ; Douer, Dan ; Zickl, Lynette ; Paietta, Elisabeth ; Rowe, Jacob M. ; Tallman, Martin S. / Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure : The ECOG experience in over 1200 patients. In: Leukemia Research. 2014 ; Vol. 38, No. 8. pp. 901-906.
@article{2ec5f8d902b84a3ba192539b7d3c282c,
title = "Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients",
abstract = "We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1{\%} of CR1 patients; 3.3{\%} of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.",
keywords = "Acute myeloid leukemia, Clinical trials, Late relapse, Normal cytogenetics, Outcomes",
author = "Watts, {Justin M.} and Wang, {Xin Victoria} and Litzow, {Mark R} and Luger, {Selina M.} and Lazarus, {Hillard M.} and Cassileth, {Peter A.} and Fernandez, {Hugo F.} and Dan Douer and Lynette Zickl and Elisabeth Paietta and Rowe, {Jacob M.} and Tallman, {Martin S.}",
year = "2014",
doi = "10.1016/j.leukres.2014.05.018",
language = "English (US)",
volume = "38",
pages = "901--906",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure

T2 - The ECOG experience in over 1200 patients

AU - Watts, Justin M.

AU - Wang, Xin Victoria

AU - Litzow, Mark R

AU - Luger, Selina M.

AU - Lazarus, Hillard M.

AU - Cassileth, Peter A.

AU - Fernandez, Hugo F.

AU - Douer, Dan

AU - Zickl, Lynette

AU - Paietta, Elisabeth

AU - Rowe, Jacob M.

AU - Tallman, Martin S.

PY - 2014

Y1 - 2014

N2 - We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.

AB - We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.

KW - Acute myeloid leukemia

KW - Clinical trials

KW - Late relapse

KW - Normal cytogenetics

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84904577671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904577671&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.05.018

DO - 10.1016/j.leukres.2014.05.018

M3 - Article

C2 - 24986381

AN - SCOPUS:84904577671

VL - 38

SP - 901

EP - 906

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -